版权说明:本文档由用户提供并上传,收益归属内容提供方,若内容存在侵权,请进行举报或认领
文档简介
BiosimilarsintheUnitedStates2023–2027COMPETITION,SAVINGS,ANDSUSTAINABILITYJANUARY2023IntroductionentdingidereheUSVIAeegratefullyacknowledged.FindOutMoreMURRAYAITKENExecutiveDirectorIQVIAInstituteforHumanDataSciencectionrightsquotationsbroadcastingpublicationsreservedNopartofthispublicationmaybereproducedortransmittedinanyformorbyanymeanselectronicormechanicalincludingphotocopyrecordingoranyinformationstorageandretrievalsystemwithoutexpresswrittenconsentofIQVIAandtheIQVIAInstitute.Overview2Marketdynamicsandbiosimilardevelopment4Factorsinfluencingbiosimilaruptake13Biosimilarimpactsonmoleculevolumeandprice20Futureimpactsofbiosimilars26Notesonsources33Definitionsandmethodology34References35Abouttheauthors36AbouttheInstitute38|3BIOSIMILARIMPACTSONMOLECULEVOLUMEANDPRICEtreatmentssweremorecostlyincludingreducingotherhealthcaresystemparticipants.Pricereductionsanddiscountsandrebates.FUTUREIMPACTSOFBIOSIMILARSmngthemesSavingsasaresultofbiosimilarsareprojectedtoexceed$180Bnoverthenextfiveyears.wthteUSMarketMarketdynamicsandbiosimilardevelopmentlbutedntadvantageavelaunchesThebiologicsmarketcontinuestogrow,with14%ofthemarketfacingbiosimilarcompetition,anumberlikelytogrowby15%in2023asbiosimilarsareexpectedtolaunchformoleculeswithhigh|5%5.6% MARKETDYNAMICSANDBIOSIMILAR%5.6% TheU.S.biologicsmarketcontinuestogrowfasterthannon-biologicsonaninvoice-basis,andnowcomprises46%ofspendingExhibit1:TotalU.S.invoicespendinggrowthbytypeandleadingtherapyareasby2021spending,US$Bns Immunologys Immunology90 Antidiabetics84 Oncology78 e ntithrombotics ntithromboticsspendingBnhealth Pain1246%%14%12%10%8%6%4%2%0%2021mallmoleculeTotalUSmedicinesInstituteNovsthmatreatmentsentsncludestherapeuticagentsaswellassupportivecareInvoicepricesinthisreportareexmanufacturerlevelreflectingthepricesbetweenanufacturersandtheircustomerswholesalersordirectpurchasersnotincludingoffinvoicediscountsandrebatesMoleculeswithbiosimilarsindevelopment$96Bn53%Biologicsmarket$260Bn47%Moleculeswithbiosimilarsindevelopment$96Bn53%Biologicsmarket$260Bn47%Moleculeswithoutbiosimilarsindevelopment$86BnMoleculeswithbiosimilarstotal$38Bnofinvoicespending,whilebiosimilardevelopmentistargetingafurther$96BnExhibit2:2021biologicsmarketsegmentedbystatusofbiosimilarcompetitionandbiosimilardevelopmentMoleculesMoleculesfacingbiosimilarcompetition$38BnMoleculesMoleculeswithpotentialfuturebiosimilars$181BnNonNon-recombinant/vaccines$41BnSourceIQVIAMIDASDecIQVIAPipelineIntelligenceIQVIAInstituteNov022.ngorsiesetogicsincludeglatirameracetateenoxaparinsodiumandarangeofvaccinesandbloodplasmaproductsNumbers|7Originatorprotected$89Bn93%Moleculeswithbiosimilarsindevelopment$96BOriginatorunprotected$7BnOriginatorprotectedOriginatorprotected$89Bn93%Moleculeswithbiosimilarsindevelopment$96BOriginatorunprotected$7BnOriginatorprotected$77Bn90%Moleculeswithoutbiosimilarsindevelopment$86BOriginatorunprotected$9BnMostofthemoleculeswithbiosimilarsindevelopmentcontinuetobeprotected,withonly7%unprotectedExhibit3:2021biologicsmarketsegmentedbystatusofbiosimilardevelopmentandmarketexclusivity21moleculesAvgsales=$4.2Bn6moleculesAvgsales=$1.2Bn145moleculesAvgsales=$532Mn33moleculesAvgsales=$260MnSourceIQVIAMIDASDecIQVIAPipelineIntelligenceIQVIAInstituteNov022.dturerewhileunprotectedisdefinedashavinganexpirydateinthepastNumbersmaynotsumduetorounding.eeBiosimilarslaunchedtodateaccountfor24%ofcompetitivemoleculevolumeExhibit4:Percentageofbiologicssalesaccessibletoapprovedandlaunchedbiosimilarsandbiosimilarefficiency,Q12015–Q3202240%5%0%5%0%5%0%chedUSVIAMIDASSepIQVIAInstituteDecalationandothersuesedeilarshareofmarketvolumewherebiosimilarsareapprovedandlaunchedandforthisexhibitiscalculatedbased|91234132312156123413142234511231212781-MARKETDYNAMICSANDBIOSIMILARDEVELOPMENT1234132312156123413142234511231212781-Since2007,30biosimilarshavelaunchedintheU.S.with10moreapprovedandsettolaunchbytheendof2023Exhibit5:BiosimilarsapprovedandlaunchedintheU.S. 1144QVIAInstituteDectedthwaysrandsimilarsapprovedbutnotyetlaunchedareplacedbasedonexpectedlaunchannouncedbycompanyApprovedetanerceptEnbrelbiosimilarsnotTherearebiosimilarsapprovedorinclinicaldevelopmentintheU.S.for20additionalmoleculesExhibit6:Cumulativemoleculespendingandapproved,launchedandpipelinebiosimilarproductsforthemolecule0255075100165-5051015MoleculesMoleculeswithlaunchedbiosimilarsMoleculeswithnolaunchedbiosimilarsDiscontinuedLaunchedApprovedbutnotlaunchedPhaseItopre-regPreclinicaltodiscoveryourceIQVIAMIDASDecIQVIAPipelineIntelligenceIQVIAInstituteDecrettedfewerpropertyissues.|11MARKETDYNAMICSANDFormoleculesfacingbiosimilars,competitivenessishighlyvariedbutlargeshareforlatercompetitorsisrareExhibit7:MarketconcentrationHerfindahl-HirschmanIndexandsharesbycompetitorQ320220.0ilarVIAMIDASSepIQVIAInstituteDectolemarkettakeineisnormalizedtoastandardizeddoseperdaytoadjustforformulationdifferencesbetweenoriginatorsandbiosimilarsericsarethosemedicinesmarketedorauthorizedbytheoriginatorusingnonproprietarynamingbutarethesameastheoriginatorproductandincludedintheoriginatorshareSomatropinhassixoriginatorproducts.MARKETDYNAMICSANDBIOSIMILARDEVELOPMENTDevelopmentofbiosimilarsisbeingdrivenbysmallercompanies,whilemarketingisdonemostlybylargecompaniesExhibit8:BiosimilarsindevelopmentandmarketedintheU.S.bycompanytypeandsize90%80%70%60%50%40%30%20%10%0%LargepharmaurceIQVIAGlobalBiosimilarsDatabaseSepIQVIAInstituteNovheonleretoicherreferstoallothercompanieswithabiosimilarindevelopmentregardless|13FactorsFactorsinfluencingbiosimilaruptakeeementdynamicsefaricsnMoleculeswithbiosimilarsfirstlaunchedin2019haveseensignificantbiosimilaruptakeinthelastthreeyears,thoughvariabilitystillexistsacrosscaresettingsintheuseofbiosimilars.FACTORSINFLUENCINGBIOSIMILARRecentbiosimilarshaveachievedhighvolumeshares,reachingmorethan60%withinthefirstthreeyears,varyingbychannelExhibit9:Biosimilarshareofvolumesincebiosimilarlaunch%80%70%60%50%40%30%20%10%0%90%80%70%60%0%024681012141618202224262830323436Monthssincebiosimilarintroductionbevacizumab7/2019filgrastim11/2013alfaMIDASIQVIADDDOctIQVIAInstituteDecMonthssincebiosimilarintroduction340BAllothers340BAllothersOverallserproductseunitshareswithoutdaysoftherapynormalizationresultingindifferencesinoverallsharecomparedtodinE|15FACTORSINFLUENCINGBIOSIMILARUPTAKEMostprovidersareusingabiosimilarofbevacizumabmorethantheoriginator,withfewfavoringtheoriginatorExhibit10:UseofbiosimilarsandoriginatorbevacizumabwithinoutletsOriginatorandbiosimilarsshareofbevacizumabvolumedistributedtooutlets2020vs.202260%50%40%30%20%10%0%BiosimilarshareOriginator2022Originator2020Biosimilars2022Biosimilars202090%80%70%60%50%40%30%20%10%0%viderpreferences.easelstialTopcombinesmaynotrepresentthesameoutlets.%80%%80%70%60%50%40%30%20%0%024681012141618202224Biosimilarshavehadstrongeruptakeinbuy-and-bill,wherephysicianshaveincentivetoselectoneproductoveranotherExhibit11:Averagebiosimilarnewpatientmarketshareovertimebybillingtype%80%70%60%50%40%30%20%10%0%024681012141618202224MonthssincelaunchBymoleculerketAccessStrategyConsultingDecents|1790%80%70%60%50%40%30%20%90%80%70%60%50%40%30%20%0%BiosimilarproductsweremorereadilyadoptedamongprofessionalproviderscomparedtoinstitutionalExhibit12:Averagebiosimilarnewpatientmarketshareovertimebyprovidertype90%80%70%60%50%40%30%20%10%0%44% 48%024681012141618202224024681012141618202224rketAccessStrategyConsultingDecorsntractingandreimbursementstoaftertwoyears.udebevacizumabepoetinalfatrastuzumabpegfilgrastiminfliximabandrituximab90%80%70%90%80%70%60%50%40%30%20%0%024681012141618202224ProvidersparticipatingintheOncologyCareModeladoptedbiosimilarsathigherlevelscomparedtonon-participantsExhibit13:AverageoncologybiosimilarnewpatientmarketshareovertimebyproviderOCMstatus90%80%70%60%50%40%30%20%10%0%024681012141618202224MonthssincelaunchrketAccessStrategyConsultingDecFFSess•ThedifferencesinuptakewerelikelydrivenbytheincentivesforOCMparticipantstoreducecosts,andOCMpracticesnotedthatutilizinglower-costbiosimilarswasarelativelyeasymethodforreducingcostspertreatment.5NotesEvaluatedbiosimilarsincludeoncologyandsupportivecarerelatedmoleculesbevacizumabepoetinalfatrastuzumabpegfilgrastim,and|19BasaglarSemgleecgBasaglarSemgleecg cInterchangeabilityhasincreasedbiosimilarusewherebiosimilaruptakehasremainedlowduetooriginatordefensestrategiesExhibit14:Insulinmonthlyshareofdefineddailydoses(DDDs)byproduct,Jan2016–Nov202290%80%90%80%70%60%50%40%30%20%0%r8%8%0%0%0%%40%0%0%0%IAMIDASNovIQVIAInstituteJanontarerotingtedicinesmarketedorauthorizedbytheoriginatorusingnonproprietarynamingbutarethesameastheoriginatorsabiosimilarapprovedthroughthebpathwaySemgleeisabiosimilarsioninLyumjevisanoriginatorlaunchedproductofinsulinogAdmelogisabiosimilarapprovedthroughthekpathwayBiosimilarBiosimilarimpactsonmoleculevolumeandpricevealternativetreatmentscanleadtovolumegenerationproducts.ingtiverIntroductionofbiosimilarsfrequentlyleadstoincreasedaccessofabiologicmedicinetopatientsdrivenbylowercostsofbiosimilarsandpricereductionsof|21aBIOSIMILARIMPACTSONMOLECULEVOLUMEANDPRICEaExhibit15:Incrementalvolumeafterbiosimilarentrycomparedtopriortrend 8642086420inestim000teriparatide8642086420 04320 1VIAMIDASSepIQVIAInstituteDecation0Percentageation001234ntexinginnovativediabetestreatments.basnangeinvolumeiscalculatedcomparingthemoleculetotalvolumetothetedvolumefromthepreexpirytrendBIOSIMILARIMPACTSONMOLECULEVOLUMEExhibit16:Quarterlyshareofdefineddailydoses(DDDs)byoriginators,secondgenerationoriginators,andbiosimilarsintheU.S.0%Neulasta*Neulasta*Neupogen*0%%40%0%0%0%90%80%70%60%50%40%30%20%10%0%PPerjetaPhesgoEnhertuHerceptin*VIAMIDASSepIQVIAInstituteDecsroductsashetathewingtandNotes:*Originatorproductwherebiosimilarsareavailableforthesamemolecule:filgrastim(Neupogen),pegfilgrastim(Neulasta),trastuzumab(Herceptin).Trastuzumabemtasine(Kadcyla)andtrastuzumabderuxtecan(Enhertu)areantibody-drugconjugates.Pertuzumab(Perjeta)isanewergenerationbreastitionPertuzumabtrastuzumabhyaluronidasePhesgoisafixeddosecombinationofPerjetaandHerceptininaectionHerceptinincludesHerceptinH|23ChangeincostperextendedunitrelativeChangeincostperextendedunitrelativetoonemonthpriortobiosimilarlaunchIntroductionofabiosimilarhasdrivendowntotalmoleculecosts18–50%withrateofdeclinedrivenbybiosimilaruptakeExhibit17:Changeincostperextendedunitfollowingbiosimilarlaunchrelativetopre-expirycost0%0%-50%04812162024283236404448525660646872768084bevacizumabepoetinalfafilgrastiminfliximabpegfilgrastimrituximabtrastuzumabSourceIQVIANationalSalesPerspectiveUSMarketAccessStrategyConsultingDec022.ngthelargest.mfiveyears.rebatesExtendedunitsrepresentnumberextendedunitswerenormalizedtotheamountofactiveingredientperextendedunit.hBIOSIMILARIMPACTSONMOLECULEVOLUMEANDPRICEhereExhibit18:OriginatorandmeanbiosimilarAverageSalesPrice(ASP)inUS$,Oct2022 Absoluteandpercentagepricedifferencebetweenoriginatorpre-expiryandbiosimilaraveragesalespricectIQVIAInstituteDecbfeofsndingpharmacymarkupsfedDecInsulinsabasofOctASPpricesnormalizedtoardbodysurfaceareameters|25hBIOSIMILARIMPACTSONMOLECULEVOLUMEhExhibit19:ChangeinoriginatorAverageSalesPrice(ASP)inUS$andvolume3%3% trastuzumab -80%-60%-40%-20%0%20%osimilarOriginatorvolumechangepre-biosimilarvs.Q32022-100%-80%-60%-40%-20%0%tIQVIAMIDASSepIQVIAInstituteDecingheaveirlyndtheseoriginators.gandardbodysurfaceareameterssquaredFutureFutureimpactsofbiosimilarsmicseSavingsfrombiosimilarsareexpectedtoexceed$180Bnoverthenextfiveyears—amorethanfour-foldincreasefromthelastfiveyears—drivenbysignificantbiosimilarlaunchesinimmunology,includingforH|27FUTUREIMPACTSOFBIOSIMILARSVolumeuptakescenariosincludehigh,mediumandlow,tiedtobothoriginatorcompetitionandpricereductionsrangingfrom15–45%Exhibit20:Modelingofscenariosbasedonaverage(basecase),highandlowexamplestodate70%24%40%0%0%0%4MIDASJunIQVIAInstituteNovareprovidersdllayersearuptakeintermsofvolumeandpricediscountsrelativetooriginatorsarebasedonIQVIAInstituteanalysisofhistoricanalogues.FUTUREIMPACTSOFBIOSIMILARSExpectedlaunchesanduptakearelikelytoincreaseoverallspendingonbiosimilarssignificantlyto$20–49Bnin2027Exhibit21:Biosimilarhistoricalsales2013–2022andoutlookscenarios2023–2027,US$Bn04MIDASJunIQVIAInstituteNovuntshnealesvaluesshownintheoutlookscenariosreflectassumptionsforhighlowandaveragebasecasevetooriginatorsTimingofexpectedbiosimilarentrybasedonpatentinformationandlitigation|29Savingsoverthenextfiveyearsasaresultofbiosimilarsareprojectedtoexceed$180Bn,thoughuncertaintiesremainExhibit22:Biologicestimatedsavingsfrombiosimilarsatinvoiceprices042.941.02.93.03.0MIDASJunIQVIAInstituteNovrstesaringactualmoleculespendingtoprojectedspendingiftotalmoleculevolumehadbeenatoriginatorpresbasedonestimatedcontinuingimpactofbiosimilareventsinprogressaswellasfutureexpectedexpiriesTherangeforhighlowandaveragebasecasebiosimilarvolumeuptakeandpriceimilarentrybasedonpatentinformationandlitigationsettlementsasofOct1%9%1%9%1%9%7%5%3%1%8%6%5%5%8%8%9%9%54%29%17%Entryofnewimmunologybiosimilarsin2023willincreasecompetitioninarapidlygrowingmarketExhibit23:Historicandfutureimmunologyvolumeindefineddailydoses(DDDs)bybiosimilarcompetition,SmallmoleculeBiologicswithbiosimilarsJunIQVIAInstituteDecetrow•Thesebiosimilarlauncheswillincreasetheshareoftotalimmunologyvolumeaccessibletobiosimilars,from25%in2022to55%in2023,andtwo-thirdsofbiologicvolumeintheimmunologymarketwillfacebiosimilarcompetition.eedhofmebasedoncurrentgrowthtrendsandtedbiosimilarentrybasedonpatentinformationandlitigationsettlementsasofO|31FUTUREIMPACTSOFBIOSIMILARSProductcharacteristicsandreimbursementdecisionsarelikelytoimpactadalimumabbiosimilaruptakebeginningin2023Exhibit24:TimelineofadalimumabbiosimilarentryandlessonsfromEuropeWaveofbiosimilarlaunches•6lowconc.:5arecitrate-free;1(possibly2)interchangeableatlaunch•2additionalhighconc.submittedtoFDA,onewithinterchangeabilityJanuarySeptemberJanuaryJulyFirstbiosimilarlaunchfree•Highconc.,interchangeabilitytrialcompletedinDec2022Laterbiosimilarsandinterchangeability•1additionallowconc.launch•PreviouslaunchedbiosimilarscouldachieveinterchangeabilityVIAMIDASSepIQVIAInstituteDecShareofadalimumabvolumeinEU4+UKbyproduct100%90%80%70%100%90%80%70%60%50%40%30%20%10%0%ehaveedroppedto30%.similarlaunchtimelinesandproductcharacteristicsbasedonpubliclyreportedcompanystatementsFDAlabelsandEMAharesinEUUKFranceGermanyItalySpainUKbasedondefineddailydosesDDDsFUTUREIMPACTSOFBIOSIMILARSBiosimilarswillcontinuetoimpactallaspectsofthehealthcaresystem,withsignificantimplicationsfromupcomingeventsExhibit25:KeybiosimilarimplicationsforstakeholdersacrossthehealthcaresystemPatientsInsurancecoverageandout-of-pocketcostsgPayersProvidersh BiosimilarcompaniesAssessingviableopportunitiesforbiosimilardevelopment(i.e.,ROI)Costvs.benefitofinterchangeabilityetAccessStrategyConsultingIQVIAInstituteDecttarsreturnon|33THISREPORTISBASEDONTHEIQVIASERVICESDETAILEDBELOWIQVIALONGITUDINALPRESCRIPTIONDATAclearinghousesrandqueplatformforassessingIQVIADRUGDISTRIBUTIONDATA(DDD)orSub-ondataproviders.IQVIA™PIPELINEINTELLIGENCEisadrugpipelineel
温馨提示
- 1. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
- 2. 本站的文档不包含任何第三方提供的附件图纸等,如果需要附件,请联系上传者。文件的所有权益归上传用户所有。
- 3. 本站RAR压缩包中若带图纸,网页内容里面会有图纸预览,若没有图纸预览就没有图纸。
- 4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
- 5. 人人文库网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。
- 6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
- 7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。
最新文档
- 2024-2030年全球与中国婴儿护肤品行业消费需求及营销前景预测报告
- 2024-2030年全球与中国二氧化硅防粘剂市场供需现状及前景规划分析报告版
- 2024-2030年免疫治疗药行业市场现状供需分析及重点企业投资评估规划分析研究报告
- 2024-2030年光电子学行业市场现状供需分析及重点企业投资评估规划分析研究报告
- 2024-2030年保温杯项目商业计划书
- 2024-2030年保险中介项目商业计划书
- 2024-2030年便携式移动放大器行业市场现状供需分析及重点企业投资评估规划分析研究报告
- 2024-2030年供应链金融行业市场发展分析及前景趋势与投资研究报告
- 2024-2030年伯乐转膜仪行业市场现状供需分析及重点企业投资评估规划分析研究报告
- 2024-2030年云服务行业市场深度调研及前景趋势与投资研究报告
- 注射用水系统再验证报告
- 虚拟现实VR技术-26张课件
- 小学英语外研新标准六年级上册(2022年新编)Module5M6U1
- 专题报告(白糖):巴西制糖业介绍
- DB42T1914-2022森林环境负氧离子浓度监测技术规范-(高清最新)
- 水泥辊压机行业分析报告
- SYT6276-1997石油天然气工业健康、安全、与环境管理体系
- 120驾驶员急救知识培训-PPT课件
- 山东中医药大学中医学(专升本)学士学位考试复习题
- 焊接——氩弧焊实训项目教学教案
- 煤炭资源地质勘探规范
评论
0/150
提交评论